Introduction
Integrins are a family of 24 heterodimeric transmembrane receptors that support cell-cell and cell-ECM (extracellular matrix) interactions in a multitude of physiological and disease αL   αX   β1   β2   β3   β7   α6  α1  α2  α3  α5  α7  α8  α9  α10  α11  α4  αE  αL  αM  αX  αD   β5  β6  β8  β1  β7  β2  β4   11D1  5C4  14E5  3E1 Integrin structure and conformational changes The first crystal structure of an integrin (V3) was solved in 2001 (Xiong et al., 2001) . The structure revealed a 'head' region, which was the main point of contact between the two subunits and comprised a -propeller fold in the -subunit and a von Willebrand factor-A domain in the -subunit (the A domain). The head was supported by two rod-like 'legs'. The -subunit leg comprised three -sandwich domains (termed thigh, calf-1 and calf-2) and the -subunit leg included a PSI (plexinsemaphorin-integrin) domain, an immunoglobulin fold (termed the hybrid domain), four epidermal growth factor (EGF)-like repeats and a cystatin-like fold (termed the -tail domain). A soluble form of the integrin was used for the crystallisation studies, but it is now well established that both integrin legs link to transmembrane domains and then to short cytoplasmic domains that can interact with each other or with cytoskeletal and signalling proteins (Wegener et al., 2007) .
Anti-integrin Monoclonal Antibodies
Interestingly, the initial crystal structure revealed a bent molecule, with articulation points in both integrin legs at the so-called genu. This form of the integrin is now thought to represent the conformation with low affinity for a ligand. The adoption of a high-affinity conformation involves a series of shape changes, including unbending of the receptor and various inter-module and intra-module movements, such as swing-out of the hybrid domain away from the -subunit and -helical movements in the A domain. Most evidence points to a separation of the cytoplasmic and transmembrane domains as a key step in the acquisition of the high-affinity conformation. It is currently unclear how many classes of integrin conformation exist, but primed and ligand-bound integrins have similar conformations, and these are distinctly different from low-affinity receptors. The poster therefore contains two general representations of integrins (bent and extended). As yet, there are no mAbs that are able to distinguish primed from ligand-bound integrins, although the relative expression of different epitopes varies between these states.
Using the prototypic peptide ligand arginineglycine-aspartate (RGD) in co-crystallisation studies, the ligand-binding pocket in V3 integrin was located at the junction of the -propeller and the A domain in the head . The aspartate carboxyl group of RGD was found to coordinate a divalent cation directly in a so-called metal-iondependent adhesion site or MIDAS. This is now accepted as a common mode of ligand binding by integrins. Half of all integrin -subunits contain an A-domain inserted into the -subunit -propeller, and for those dimers that contain this A domain, the module has evolved to incorporate the main ligand-binding site through a very similar mechanism to that of the A domain. Intriguingly, ligand binding to the A domain causes engagement of the A domain by an intramolecular pseudo-ligand (a glutamate residue at the base of the A domain) and therefore relays ligand binding to the -subunit (Alonso et al., 2002) . Thus, the conformational changes that underpin changes in integrin activation state are common to all receptors.
Mechanism of action of regulatory mAbs
Stimulatory or activation-specific mAbs Whereas all stimulatory or activation-specific mAbs appear to increase ligand-binding affinity by reducing off-rate (i.e. the rate of dissociation), the reagents fall into two subclasses (Humphries, 2000) . One subclass recognises epitopes that are regulated by ligand and cation binding. The epitopes for these mAbs are frequently termed LIBS (ligand-induced binding sites). A second subclass is not affected by ligand or cation binding (this includes the widely used anti-1 mAb, TS2/16). It is probable that cation-and ligand-regulated mAbs recognise conformations of integrins that are found in either the primed or ligand-occupied state, and that they therefore shift a conformational equilibrium in favour of those forms. The epitopes might be created de novo as a result of movement of secondary structure elements within protein modules (e.g. within the A domain) or by exposure of masked epitopes (e.g. as a result of leg separation, unbending or domain movement). Inevitably, any mAb that binds preferentially to the high-affinity form of the receptor will activate integrin by skewing the conformational equilibrium. However, some might appear to lack stimulatory activity either because the equilibrium might already be fully displaced towards the high-affinity state or because the cell type tends to exhibit all-or-none-type activation responses (e.g. mAb 24 and leukocyte 2 integrins).
A special subclass of cation-and ligandregulated mAbs are those that contain ligand-mimetic peptide sequences within their complementarity-determining loops (e.g. PAC-1 and WOW-1, which recognise 3; and 6.8G6, which binds 6). These reagents are particularly useful for detecting high-affinity conformations of integrins because they effectively act as ligands. However, these mAbs also block binding because they compete directly for ligand occupancy. The binding of non-ligand-regulated mAbs probably induces a primed conformation in the integrin by forcing shape changes rather than by stabilising naturally occurring conformations. Most stimulatory mAbs recognise sites throughout the -subunit, implying that major changes take place in this region of the receptor. Key sites that are recognised by ligand-regulated mAbs include the PSI domain (which is partly buried in the bent form), the A domain (in which movement of its 1 and 7 helices create new epitopes), the hybrid domain (in which swingout exposes epitopes), the genu (which is masked in the bent form) and the EGF-like repeats (which are partly covered in the bent form). Although most activating mAbs recognise the -subunit, activating anti--subunit mAbs do exist, with examples that affect conformation of the A domain or detect leg separation. Thus, the choice of stimulatory mAbs for research purposes should be informed by the mechanism of action of the mAb, and this is generally determined by the location of its epitopes. The acquisition of a high-affinity state is best achieved using mAbs that stabilise an extended conformation or that stabilise the highaffinity form of the A domain.
Inhibitory mAbs
It is generally assumed that inhibitory mAbs sterically interfere with ligand binding and therefore act as competitive inhibitors. Surprisingly, of those anti-integrin mAbs on which detailed analyses have been performed, most act as allosteric inhibitors (Mould et al., 1996) . In this case, mAbs appear to prevent the conformational changes that are needed for ligand binding to occur, and they might therefore stabilise the unoccupied state of the receptor. Although many inhibitory mAbs are allosteric inhibitors, their epitopes are usually very close to ligand contact sites. Similarly to stimulatory mAbs, some of these epitopes are regulated by ligand and cation binding and are termed LABS (ligand-attenuated binding sites). There are also a few examples of mAbs that recognise the high-affinity conformation of integrins, but their binding blocks ligand engagement (e.g. 12F1, which recognises 2; and CBRM1/5, which binds M).
Non-functional mAbs
The use of the most appropriate non-functional integrin mAb is of paramount importance for the correct interpretation of data relating to the study of integrin regulation and function. These reagents therefore constitute the best type of control and, where available, a mAb directed against the same subunit and domain of the integrin of interest should be used. There are relatively few non-functional mAbs reported, and the choice of reagents can therefore be limited. The reason for this paucity is probably the conformationally dynamic nature of integrins, with stabilisation of many conformations, even distal from the main sites of ligand binding, having a resultant effect on integrin function.
Therapeutics
Integrin-based cell adhesion contributes to the pathogenesis of a wide spectrum of human disorders. mAbs that block integrin functions have been shown to be of clinical benefit for the treatment of thrombotic and autoimmune disorders, with total sales of anti-integrin antibodies for therapeutic use exceeding $1 billion in 2008 (La Merie, 2009 ). Antiintegrin mAbs that are currently in clinical use are ReoPro (abciximab) and Tysabri (natalizumab). ReoPro is a humanised version of a function-blocking mAb (7E3) that recognises the 3 subunit and blocks the platelet fibrinogen receptor IIb3; it is used in the treatment of unstable angina and as an adjuvant to percutaneous coronary interventions. The epitope of 7E3 includes residues on the top face of the 3 subunit A-domain, close to the MIDAS site (Artoni et al., 2004) . Tysabri is an inhibitory mAb that recognises the 4 subunit and is used in the treatment of relapsing forms of multiple sclerosis. Blockade of T-cell 41 integrin prevents these cells from entering the central nervous system, thereby slowing the destruction of nerve sheaths. The epitope of Tysabri lies in the -propeller domain of the 4 subunit (Huryn et al., 2004) . A number of other functionblocking antibodies are currently at preclinical stages of development for the treatment of cancer and fibrosis. In the future, it is likely that antibodies that stimulate integrin function will also find clinical uses, such as enhancing repair in the central nervous system (Andrews et al., 2009 ).
Perspectives
Integrin mAbs have contributed immensely to our understanding of integrin activation-state regulation, integrin biology and integrin-based therapeutics. Nonetheless, much is still to be learned, for example regarding what differentiates conformation-specific signals. The development of new mAbs that can discriminate between these signals would undoubtedly aid progress in this area and might also reveal new avenues for therapeutic intervention. It is noteworthy that mAbs that recognise certain integrin subunits or heterodimer activation states (e.g. ligandmimetic 1 mAbs or activation-specific -subunit mAbs) are at present missing or under-represented in the arsenal of available mAbs, and their production would shed further light on many areas of integrin biology. Moving forward, it is apparent that global systems-based analyses of the complexity of integrin signalling is both required and informative, and the use of integrin mAbs in such studies might help to elucidate activation-state-specific signalling complexes and pathways.
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